Emyria (ASX: EMD) has reported compelling 6-month follow-up results from its innovative treatment program for patients with treatment-resistant post-traumatic stress disorder (PTSD). Key outcomes include: · 63% of patients no longer met the clinical criteria for PTSD · 55.5% average reduction in symptom severity (PCL-5) · 121.5% improvement in quality of life (ReQoL-10) · All side effects were mild, short-lived, and resolved under supervision These results reflect durable recovery in a real-world setting. To support further clinical validation and research, Emyria has signed an MOU with ANU, focused on expanding access, clinician training, and development of new care protocols.
Link to the Announcement: Click Here